Endocannabinoids measurement in human saliva as potential biomarker of obesity

Isabelle Matias, Blandine Gatta-Cherifi, Antoine Tabarin, Samantha Clark, Thierry Leste-Lasserre, Giovanni Marsicano, Pier Vincenzo Piazza, Daniela Cota, Isabelle Matias, Blandine Gatta-Cherifi, Antoine Tabarin, Samantha Clark, Thierry Leste-Lasserre, Giovanni Marsicano, Pier Vincenzo Piazza, Daniela Cota

Abstract

Background: The discovery of the endocannabinoid system and of its role in the regulation of energy balance has significantly advanced our understanding of the physiopathological mechanisms leading to obesity and type 2 diabetes. New knowledge on the role of this system in humans has been acquired by measuring blood endocannabinoids. Here we explored endocannabinoids and related N-acylethanolamines in saliva and verified their changes in relation to body weight status and in response to a meal or to body weight loss.

Methodology/principal findings: Fasting plasma and salivary endocannabinoids and N-acylethanolamines were measured through liquid mass spectrometry in 12 normal weight and 12 obese, insulin-resistant subjects. Salivary endocannabinoids and N-acylethanolamines were evaluated in the same cohort before and after the consumption of a meal. Changes in salivary endocannabinoids and N-acylethanolamines after body weight loss were investigated in a second group of 12 obese subjects following a 12-weeks lifestyle intervention program. The levels of mRNAs coding for enzymes regulating the metabolism of endocannabinoids, N-acylethanolamines and of cannabinoid type 1 (CB(1)) receptor, alongside endocannabinoids and N-acylethanolamines content, were assessed in human salivary glands. The endocannabinoids 2-arachidonoylglycerol (2-AG), N-arachidonoylethanolamide (anandamide, AEA), and the N-acylethanolamines (oleoylethanolamide, OEA and palmitoylethanolamide, PEA) were quantifiable in saliva and their levels were significantly higher in obese than in normal weight subjects. Fasting salivary AEA and OEA directly correlated with BMI, waist circumference and fasting insulin. Salivary endocannabinoids and N-acylethanolamines did not change in response to a meal. CB(1) receptors, ligands and enzymes were expressed in the salivary glands. Finally, a body weight loss of 5.3% obtained after a 12-weeks lifestyle program significantly decreased salivary AEA levels.

Conclusions/significance: Endocannabinoids and N-acylethanolamines are quantifiable in saliva and their levels correlate with obesity but not with feeding status. Body weight loss significantly decreases salivary AEA, which might represent a useful biomarker in obesity.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Fasting salivary endocannabinoids and N…
Figure 1. Fasting salivary endocannabinoids and N-acylethanolamines are elevated in obese subjects.
Fasting salivary and plasma AEA (A), 2-AG (B), PEA (C) and OEA (D) levels in normal weight and obese subjects. *p<0.05, **p<0.01, ***p<0.001.
Figure 2. Relationship of salivary AEA and…
Figure 2. Relationship of salivary AEA and OEA levels with anthropometric and metabolic parameters.
Fasting salivary AEA and OEA correlation with body mass index (BMI) (A, D), waist circumference (B, E) and fasting insulin levels (C, F).
Figure 3. The ECS is present in…
Figure 3. The ECS is present in human salivary glands.
(A) RT-PCR for CB1, FAAH, MAGL, DAGL alpha, DAGL beta and housekeeping genes GAPDH and HRPT performed on submandibular and accessory salivary glands. (B) RT-PCR for NAPE-PLD and NAAA performed on submandibular and accessory salivary glands. A 100-bp ladder is shown. (C) Endocannabinoids and related N-acylethanolamines content in submandibular salivary glands. CB1: Cannabinoid receptor type 1, DAGL alpha: Diacylglycerol lipase alpha, DAGL beta: Diacylglycerol lipase beta, FAAH: Fatty acid amide hydrolase, GAPDH: glyceraldehyde-phosphate dehydrogenase, HPRT: hypoxanthine phosphoribosyl transferase, MAGL: Monoacylglycerol lipase, NAAA: N-acylethanolamine-hydrolyzing acid amidase, NAPE-PLD: N-acyl phosphatidylethanolamine phospholipase D.
Figure 4. Changes in salivary endocannabinoids and…
Figure 4. Changes in salivary endocannabinoids and N-acylethanolamines levels in response to a meal.
Salivary AEA (A), 2-AG (B), OEA (C) and PEA (D) levels 1 h before (1 h PRE), immediately before (PRE) and 1 h after the termination of the meal (1 h POST). *p<0.05 normal weight vs. obese at a specific time point; #p<0.05, ##p<0.01 normal weight vs. obese.
Figure 5. Changes in salivary endocannabinoids and…
Figure 5. Changes in salivary endocannabinoids and N-acylethanolamines levels in response to body weight loss.
Salivary AEA (A), 2-AG (B), PEA (C) and OEA (D) before and after body weight loss obtained through a 12 weeks life-style intervention program. *p<0.05 before vs. after the lifestyle intervention program.

References

    1. Bermudez-Silva FJ, Cardinal P, Cota D (2012) The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 26: 114–124.
    1. Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U (2011) Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 17: 518–526.
    1. Kunos G, Tam J (2011) The case for peripheral CB receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163: 1423–1431.
    1. Di Marzo V, Piscitelli F, Mechoulam R (2011) Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 75–104.
    1. Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585–589.
    1. Matias I, Bisogno T, Di Marzo V (2006) Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 30 Suppl 1: S7–S12.
    1. Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, et al. (2007) Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 152: 676–690.
    1. Cote M, Matias I, Lemieux I, Petrosino S, Alméras N, et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692–699.
    1. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, et al. (2010) Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 5: e8792.
    1. Gatta-Cherifi B, Matias I, Vallee M, Tabarin A, Marsicano G, et al. (2012) Synergistic post-prandial deregulation of orexigenic and anorexigenic systems in obesity. Int J Obes (Lond) 36: 880–885.
    1. Spielmann N, Wong DT (2011) Saliva: diagnostics and therapeutic perspectives. Oral Dis 17: 345–354.
    1. Lawrence HP (2002) Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 68: 170–174.
    1. Acosta A, Hurtado MD, Gorbatyuk O, La Sala M, Duncan D, et al. (2011) Salivary PYY: a putative bypass to satiety. PLoS One 6: e26137.
    1. Li BB, Chen ZB, Li BC, Lin Q, Li XX, et al. (2011) Expression of ghrelin in human salivary glands and its levels in saliva and serum in Chinese obese children and adolescents. Arch Oral Biol 56: 389–394.
    1. Benedix F, Westphal S, Patschke R, Granowski D, Luley C, et al. (2011) Weight loss and changes in salivary ghrelin and adiponectin: comparison between sleeve gastrectomy and Roux-en-Y gastric bypass and gastric banding. Obes Surg 21: 616–624.
    1. Marczylo TH, Lam PM, Nallendran V, Taylor AH, Konje JC (2009) A solid-phase method for the extraction and measurement of anandamide from multiple human biomatrices. Anal Biochem 384: 106–113.
    1. Lam PM, Marczylo TH, Konje JC (2010) Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 398: 2089–2097.
    1. Fezza F, Dillwith JW, Bisogno T, Tucker JS, Di Marzo V, et al. (2003) Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. Biochim Biophys Acta 1633: 61–67.
    1. Prestifilippo JP, Fernandez-Solari J, Medina V, Rettori V, Elverdin JC (2009) Role of the endocannabinoid system in ethanol-induced inhibition of salivary secretion. Alcohol Alcohol 44: 443–448.
    1. Prestifilippo JP, Fernandez-Solari J, de la Cal C, Iribarne M, Suburo AM, et al. (2006) Inhibition of salivary secretion by activation of cannabinoid receptors. Exp Biol Med (Maywood) 231: 1421–1429.
    1. Dall'Aglio C, Mercati F, Pascucci L, Boiti C, Pedini V, et al. (2010) Immunohistochemical localization of CB1 receptor in canine salivary glands. Vet Res Commun 34 Suppl 1: S9–12.
    1. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ (2003) Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102: 211–216.
    1. Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178: 107–115.
    1. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, et al. (2008) Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781: 200–212.
    1. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.
    1. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, et al. (2011) Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 34: 2152–2157.
    1. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171–3180.
    1. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (2004) Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279: 5298–5305.
    1. Ueda N, Yamanaka K, Yamamoto S (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276: 35552–35557.
    1. Schwartz GJ (2011) Gut fat sensing in the negative feedback control of energy balance–recent advances. Physiol Behav 104: 621–623.
    1. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, et al. (2005) Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci 62: 708–716.
    1. Yoshida R, Ohkuri T, Jyotaki M, Yasuo T, Horio N, et al. (2010) Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci U S A 107: 935–939.
    1. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, et al. (2008) The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8: 281–288.
    1. DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D (2011) Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A 108: 12904–12908.
    1. Fernandez-Solari J, Prestifilippo JP, Ossola CA, Rettori V, Elverdin JC (2010) Participation of the endocannabinoid system in lipopolysaccharide-induced inhibition of salivary secretion. Arch Oral Biol 55: 583–590.
    1. Modeer T, Blomberg CC, Wondimu B, Julihn A, Marcus C (2010) Association between obesity, flow rate of whole saliva, and dental caries in adolescents. Obesity (Silver Spring) 18: 2367–2373.
    1. Powers PS, Holland P, Miller C, Powers HP (1982) Salivation patterns of obese and normal subjects. Int J Obes 6: 267–270.
    1. Wooley OW, Wooley SC, Dunham RB (1976) Deprivation, expectation and threat: effects on salivation in the obese and nonobese. Physiol Behav 17: 187–193.
    1. Epstein LH, Paluch R, Coleman KJ (1996) Differences in salivation to repeated food cues in obese and nonobese women. Psychosom Med 58: 160–164.
    1. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838–2843.
    1. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, et al. (2009) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52: 213–217.
    1. Jumpertz R, Wiesner T, Bluher M, Engeli S, Bátkai S, et al. (2010) Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea–specific role of oleoylethanolamide. Exp Clin Endocrinol Diabetes 118: 591–595.
    1. Joosten MM, Balvers MG, Verhoeckx KC, Hendriks HF, Witkamp RF (2010) Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab (Lond) 7: 49.
    1. Fanelli F, Di Lallo VD, Belluomo I, De Iasio R, Baccini M, et al. (2012) Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res 53: 481–493.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner